VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
Standard
VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients. / Ding, Yi; Schmalfeldt, Barbara; Vettorazzi, Eike; Legler, Karen; Milde-Langosch, Karin; Woelber, Linn; Jaeger, Anna; Prieske, Katharina; Mueller, Volkmar; Schmalfeldt, Barbara; Kuerti, Sascha.
in: PLOS ONE, Jahrgang 17, Nr. 6, e0269680, 2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
AU - Ding, Yi
AU - Schmalfeldt, Barbara
AU - Vettorazzi, Eike
AU - Legler, Karen
AU - Milde-Langosch, Karin
AU - Woelber, Linn
AU - Jaeger, Anna
AU - Prieske, Katharina
AU - Mueller, Volkmar
AU - Schmalfeldt, Barbara
AU - Kuerti, Sascha
PY - 2022
Y1 - 2022
N2 - OBJECTIVE: At present, maintenance therapy with the antiangiogenic agent bevacizumab or with PARP-inhibitors represent two options for BRCA-wildtype ovarian cancer patients, after platinum-based first line chemotherapy. The identification of molecular markers to predict patient response to different maintenance therapies remains a major challenge. In the present study we analyzed the predictive potential of vascular endothelial growth factor C (VEGF-C) to identify ovarian cancer patients that might benefit from an antiangiogenic therapy.METHODS: 101 patients with primary epithelial ovarian cancer were analyzed for serum levels of VEGF-A,-C and CA-125 by ELISA. Serum levels were compared between patients with low pT-stage (pT1a-pT2c n = 11), healthy individuals (n = 27) and patients with higher pT-stage (> = pT3 n = 90). Adjusted ROC curves and an adjusted logistic regression model were carried out to evaluate the potential impact of VEGF-A and -C, as well as CA-125 serum level concentration on bevacizumab-therapy response, under consideration of covariates such as FIGO, pM, pN and residual tumor after surgery.RESULTS: A patient which has in comparison twice the VEGF-C concentration in serum, has a significant increased chance of response to bevacizumab by a factor of 2.79. Further, only VEGF-C serum levels were significantly higher in the group of patients with lower pT-stage compared to healthy individuals, whereas VEGF-A or CA-125 serum levels could not discriminate between healthy individuals and patients with ovarian cancer at low pT-stages.CONCLUSION: VEGF-C serum level might serve as as a biomarker to evaluate treatment response under bevacizumab.
AB - OBJECTIVE: At present, maintenance therapy with the antiangiogenic agent bevacizumab or with PARP-inhibitors represent two options for BRCA-wildtype ovarian cancer patients, after platinum-based first line chemotherapy. The identification of molecular markers to predict patient response to different maintenance therapies remains a major challenge. In the present study we analyzed the predictive potential of vascular endothelial growth factor C (VEGF-C) to identify ovarian cancer patients that might benefit from an antiangiogenic therapy.METHODS: 101 patients with primary epithelial ovarian cancer were analyzed for serum levels of VEGF-A,-C and CA-125 by ELISA. Serum levels were compared between patients with low pT-stage (pT1a-pT2c n = 11), healthy individuals (n = 27) and patients with higher pT-stage (> = pT3 n = 90). Adjusted ROC curves and an adjusted logistic regression model were carried out to evaluate the potential impact of VEGF-A and -C, as well as CA-125 serum level concentration on bevacizumab-therapy response, under consideration of covariates such as FIGO, pM, pN and residual tumor after surgery.RESULTS: A patient which has in comparison twice the VEGF-C concentration in serum, has a significant increased chance of response to bevacizumab by a factor of 2.79. Further, only VEGF-C serum levels were significantly higher in the group of patients with lower pT-stage compared to healthy individuals, whereas VEGF-A or CA-125 serum levels could not discriminate between healthy individuals and patients with ovarian cancer at low pT-stages.CONCLUSION: VEGF-C serum level might serve as as a biomarker to evaluate treatment response under bevacizumab.
KW - Angiogenesis Inhibitors/therapeutic use
KW - Bevacizumab/therapeutic use
KW - CA-125 Antigen
KW - Carcinoma, Ovarian Epithelial/drug therapy
KW - Female
KW - Humans
KW - Ovarian Neoplasms/pathology
KW - Vascular Endothelial Growth Factor A/metabolism
KW - Vascular Endothelial Growth Factor C
U2 - 10.1371/journal.pone.0269680
DO - 10.1371/journal.pone.0269680
M3 - SCORING: Journal article
C2 - 35687576
VL - 17
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 6
M1 - e0269680
ER -
